{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:13:09Z","timestamp":1787008389142,"version":"build-2736575974"},"reference-count":14,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":3130,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["5U10 CA11488-27"],"award-info":[{"award-number":["5U10 CA11488-27"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["5U10 CA011488-40"],"award-info":[{"award-number":["5U10 CA011488-40"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004898","name":"EORTC Charitable Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004898","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1093\/annonc\/mdq575","type":"journal-article","created":{"date-parts":[[2010,11,9]],"date-time":"2010-11-09T00:39:10Z","timestamp":1289263150000},"page":"1054-1061","source":"Crossref","is-referenced-by-count":134,"title":["A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)"],"prefix":"10.1016","volume":"22","author":[{"given":"G.","family":"Daugaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Skoneczna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Aass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"De Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Dumez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marreaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Collette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.G.","family":"Lluch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"Schmoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq575_bb0010","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.1997.15.2.594","article-title":"International Germ Cell Classification: a prognostic factor-based staging system for metastatic germ-cell cancers","volume":"15","author":"International Germ Cell Collaborative Group","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq575_bb0015","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/0959-8049(93)90211-W","article-title":"A phase I\/II study of stepwise dose-escalet regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours","volume":"29","author":"Bokemeyer","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdq575_bb0020","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1200\/JCO.2003.09.035","volume":"21","author":"Schmoll","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq575_bb0025","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1200\/JCO.1999.17.11.3450","article-title":"First-line high-dose chemotherapy compared with standard-dose PEB\/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis","volume":"17","author":"Bokemeyer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq575_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"key":"10.1093\/annonc\/mdq575_bb0035","series-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"2002"},{"key":"10.1093\/annonc\/mdq575_bb0040","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdq575_bb0045","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials","volume":"35","author":"O'Brien","year":"1979","journal-title":"Biometrics"},{"key":"10.1093\/annonc\/mdq575_bb0050","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.2001.19.9.2534","article-title":"Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy","volume":"19","author":"Mazumdar","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq575_bb0055","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.1989.7.7.932","article-title":"Dose-intensive chemotherapy in refractory germ cell cancer: a phase I\/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation","volume":"7","author":"Nichols","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq575_bb0060","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1200\/JCO.2006.09.2148","article-title":"Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group","volume":"25","author":"Lorch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq575_bb0065","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa067749","article-title":"High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors","volume":"357","author":"Einhorn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq575_bb0070","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2005.05.4528","article-title":"Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous stem-cell rescue as first-line treatment for patients with poor prognosis metastatic germ cell cancer","volume":"25","author":"Motzer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq575_bb0075","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/jnci\/91.10.839","volume":"91","author":"Collette","year":"1999","journal-title":"J Natl Cancer Inst"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419385229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419385229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/5\/1054\/428887\/mdq575.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T05:20:57Z","timestamp":1624684857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419385229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0923753419385229"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq575","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}